Recordati Rare Diseases

Recordati Rare Diseases is a global biopharmaceutical company dedicated to providing treatment options for patients with rare and orphan diseases. As a specialized division of the Recordati Group, the company focuses on high-unmet-need areas including metabolic disorders, endocrinology, and rare oncology. Its commercial portfolio is anchored by key products such as Isturisa and Signifor for Cushing’s syndrome, and Carbaglu for urea cycle disorders. The company expanded its oncology footprint significantly through the acquisition of EUSA Pharma, adding treatments like Qarziba for high-risk neuroblastoma. Recordati Rare Diseases operates with a 'patient-first' philosophy, maintaining a presence in over 100 countries to ensure access to life-altering therapies.